The PHARMO Institute joins Lumanity, strengthening Lumanity’s RWE Capabilities
The PHARMO Institute is excited to announce that it is now part of Lumanity, a
30 July 2024
The PHARMO Institute is excited to announce that it is now part of Lumanity, a
See you in Halifax at ICPE 2023! We are proud to be a Gold sponsor
The PHARMO Institute and Lumanity are Partnering to Invest in new Solutions to Support Enhanced
Myocarditis and pericarditis associated with SARS-CoV-2 vaccines Together with colleagues across Europe we have recently
The DIAbetes MANagement and Treatment (DIAMANT) Cohort The DIAbetes MANagement and Treatment (DIAMANT) Cohort is
Real-world data of HER2-low metastatic breast cancer: A population based cohort study In this study,
Complex drug use The number of people using medicines and combinations of medicines is increasing,
At ISPOR Europe 2022 in Vienna, the INTREPID Trial study, to which the PHARMO Institute
This study describes treatment patterns, low-density lipoprotein cholesterol (LDL-C) levels and healthcare resource utilization (HCRU)
“More and more people are living with cancer. It is expected that the number of